Evidence map›Paper›PMID 11122798›Full record

ReviewCurrent oncology reports1999

Dose-intensive approaches to ovarian cancer.

N Lambrou, E L Trimble

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current oncology reports, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Treatment of peritoneal carcinomatosis from ovarian cancer. Present, future directions and proposals.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2007
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

N LambrouDepartment of Gynecology and Obstetrics, The Johns Hopkins Hospital, Phipps 248, 600 North Wolfe Street, Baltimore, MD 21287, USA.
E L Trimble
National Cancer Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increasing the total dose or the dose intensity of platinum does not improve survival in women with ovarian cancer. High-dose chemotherapy with hematologic support has not been shown to be more effective than standard-dose chemotherapy. Regional dose intensity, through intraperitoneal chemotherapy, may have a role in the treatment of advanced ovarian cancer. Further studies are needed to identify the optimal combination of agents, in addition to a platinum and a taxane, to be used in primary therapy for ovarian cancer.

Indexed as

AnthracyclinesAntineoplastic Combined Chemotherapy ProtocolsClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicCyclophosphamideDeoxycytidineDose-Response Relationship, DrugEtoposideFemaleGemcitabineHumansOvarian NeoplasmsPrognosisSurvival AnalysisTopotecanAnthracyclinesCyclophosphamideDeoxycytidineEtoposideGemcitabineTopotecan

Identifiers

PMID11122798
OpenAlexW1995085344

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.